Parra-Lara Luis Gabriel, Falla-Martínez Juan Camilo, Isaza-Pierotti Daniel Francisco, Mendoza-Urbano Diana Marcela, Tangua-Arias Andrés R, Bravo Juan Carlos, Bravo Luis Eduardo, Zambrano Ángela R
Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.
Front Oncol. 2023 Mar 7;13:1069369. doi: 10.3389/fonc.2023.1069369. eCollection 2023.
Gastric adenocarcinoma (GA) has changed in recent decades. Cancer estimates are often calculated from population-based cancer registries, which lack valuable information to guide decision-making (clinical outcomes). We describe the trends in clinical practice for GA using a hospital-based cancer registry over a timespan of 15 years.
A retrospective cohort study was conducted. Data were gathered from adults diagnosed and treated for GA at Fundación Valle del Lili (FVL), between 2000 and 2014, from the hospital's own cancer registry and crossed with Cali's Cancer Registry. Additional data were obtained directly from clinical records, pathology reports and the clinical laboratory. Patients younger than 18 years and those for whom limited information was available in the medical history were excluded. A survival analysis was conducted using Kaplan-Meier method.
A total of 500 patients met eligibility criteria. Median age was 64 years (IQR: 54-74 years), 39.8% were female, 22.2% were at an early stage, 32.2% had a locally advanced disease, and 29% a metastatic disease, 69% had intestinal subtype, 48.6% had a positive test, 85.2% had a distal lesion, 62% underwent gastrectomy, 60.6% lymphadenectomy, and 40.6% received chemotherapy. Survival at 5 years for all cases was 39.9% (CI 95% 35.3-44.5). Survival decreased over time in all groups and was lower in age-groups <39 and 60-79 with either locally advanced or metastatic disease. Prognostic factors that were significant in the Cox proportional-hazards model were late stages of the tumor (locally advanced: HR=2.52; metastatic: HR=4.17), diffuse subtype (HR=1.40), gastrectomy (subtotal: HR=0.42; total: 0.44) and palliative chemotherapy (HR=0.61).
The treatment of GA has changed in recent decades. GA survival was associated with clinical staging, diffuse subtype, gastrectomy and palliative chemotherapy. These findings must be interpreted in the context of a hospital-based study.
近几十年来,胃腺癌(GA)情况有所变化。癌症估计数通常根据基于人群的癌症登记处数据计算得出,而这些数据缺乏指导决策(临床结果)的有价值信息。我们利用一家医院的癌症登记处数据描述了15年间GA的临床实践趋势。
开展了一项回顾性队列研究。收集了2000年至2014年间在巴耶德尔利基金会(FVL)被诊断并接受GA治疗的成年患者的数据,这些数据来自该医院自己的癌症登记处,并与卡利癌症登记处的数据进行了交叉比对。另外的数据直接从临床记录、病理报告和临床实验室获取。排除了年龄小于18岁的患者以及病史信息有限的患者。采用Kaplan-Meier方法进行生存分析。
共有500名患者符合纳入标准。中位年龄为64岁(四分位间距:54 - 74岁),女性占39.8%,早期患者占22.2%,局部进展期患者占32.2%,转移性疾病患者占29%,69%为肠型,48.6%检测呈阳性,85.2%为远端病变,62%接受了胃切除术,60.6%接受了淋巴结清扫术,40.6%接受了化疗。所有病例的5年生存率为39.9%(95%置信区间35.3 - 44.5)。所有组的生存率均随时间下降,在年龄小于39岁以及60 - 79岁的局部进展期或转移性疾病患者中生存率更低。在Cox比例风险模型中具有显著意义的预后因素为肿瘤晚期(局部进展期:风险比=2.52;转移性:风险比=4.17)、弥漫型(风险比=1.40)、胃切除术(次全切除:风险比=0.42;全切除:0.44)和姑息化疗(风险比=0.61)。
近几十年来GA的治疗情况有所变化。GA的生存与临床分期、弥漫型、胃切除术和姑息化疗相关。这些发现必须在基于医院的研究背景下进行解读。